First — here’s the report summary:
. . . .Introduction
The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer’s Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials. . . .
Some 40% of the entire seven major market antidyslipidemic market is commanded by Lipitor, the gold standard therapy and highest selling agent among statins and antidyslipidemics in general. This will change dramatically after the loss of its patent protection in 2010/2011, reducing Lipitor’s market share to 9% only by 2017.
The top 10 brands accounted for 81% of the market in 2007; the top revenue generating agents include Lipitor, Vytorin, Crestor, Zetia and Tricor. Over the forecast period the share of the brands in the antidyslipidemic market is expected to fall due to the further genericization.
The recent ENHANCE trial results have added to the distressing effects of genericization, while at the same time curbing the sales of Zetia and Vytorin, and further undermining confidence in the surrogate markers of atherosclerosis. This event is likely to make the ever-stricter process of approval for new agents even harder. . . .
Now, my answer to PM’s poser:
That’s who. Carry-on!